News

Otsuka's Novel DprE1 Inhibitor Shows Promising Anti-Tuberculosis Activity

On May 21st, Antimicrbial Agents and Chemotherapy published an article on Otsuka's novel anti-tuberculosis compound, OPC-167832. This molecule, a DprE1 inhibitor, demonstrated potent bactericidal activity and exhibited significant combination effects in 2-drug combinations with delamanid, bedaquiline, or levofloxacin. Additionally, 3- or 4- drug regimens comprising of delamanid and OPC-167832 as the core along with bedaquiline, moxifloxacin, or linezolid showed efficacy in reducing the bacterial burden and preventing relapse superior to that of the standard treatment regimen. 

To read the full article Antimicrobial Agents and Chemotherapy article, please click here: OPC-167832, a Novel Carbostyril Derivative with Potent Antituberculosis Activity as a DprE1 Inhibitor

More News
23 Aug 2022
Last week, the PAN-TB collaboration announced initial plans for a Phase 2 clinical trial evaluating two novel drug regimens to treat Tuberculosis. Sponsored by the Bill and Melinda Gates Foundation, the PAN-TB, or “Project to Accelerate New Treatments for Tuberculosis”, collaboration brings...
4 May 2022
Earlier this week, the World Health Organization (WHO) released a rapid communication which detailed the upcoming changes to the treatment guidance for drug-resistant tuberculosis (DR-TB). These guidelines are used to inform national TB programmes globally on how to treat patients with these...
5 Apr 2022
On April 01, 2022, the Stop TB Partnership launched the second online consultation for the new Global Plan to End TB 2023-2030. Over the years, the Global Plans have been important tools for advocacy and resource mobilization, and served as a reference document for donors and stakeholders. In May...